

CB 1611 # 8  
10/7/99  
Patent 82  
238/130

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Peng Cho Tang et al.

Serial No.: 09/191,199 ✓

Filed: November 12, 1998 ✓

For: 3-HETEROARYLIDENEAZAINDOLIN-2-  
ONE TYROSINE KINASE INHIBITORS ✓



Group Art Unit: 1611

Examiner: To be assigned

RECEIVED

R

SEP 29 1998

TECH CENTER 1600/2900

TEL.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.97-98, the following information is brought to the attention of the Examiner. The item is listed on the attached form PTO-1449 and a copy is enclosed for the convenience of the Examiner.

The items identified in this Supplemental Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is

SD-125091.1

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

September 22, 1999

Date of Deposit

Karen M. Cruz

Name of Person Mailing Paper

Signature of Person Mailing Paper

material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Supplemental Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b) (3) before the mailing of a first Office Action on the merits, whereby no petition or fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is requested to consider this a petition and he is authorized to charge any required petition fee to counsel's Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: September 21, 1999

By: 

Charles S. Berkman  
Reg. No. 38,077

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(213) 489-1600